News
01-19-2012, 12:10 PM
Patients with HER2-positive breast cancer have been treated with Tykerb (lapatinib) both in combination with herceptin (trastuzumab), and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy...
More... (http://www.medicalnewstoday.com/articles/240518.php)
More... (http://www.medicalnewstoday.com/articles/240518.php)